Secondary eradication of Helicobacter pylori was effective against refractory idiopathic thrombocytopenic purpura.
Asaumi
Noboru
N
Niiya
Kenji
K
Shibakura
Misako
M
Yoshida
Chikamasa
C
Niiya
Masami
M
Tanimoto
Mitsune
M
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001792:Blood Platelets / Q000187:drug effects; D004359:Drug Therapy, Combination; D016481:Helicobacter Infections / Q000097:blood / Q000188:drug therapy*; D016480:Helicobacter pylori; D006801:Humans; D064747:Lansoprazole; D008297:Male; D008875:Middle Aged; D008911:Minocycline / Q000627:therapeutic use*; D015242:Ofloxacin / Q000627:therapeutic use*; D009853:Omeprazole / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D010976:Platelet Count; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000097:blood / Q000188:drug therapy* / Q000382:microbiology
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000900:Anti-Bacterial Agents; D064747:Lansoprazole; D015242:Ofloxacin; D008911:Minocycline; D009853:Omeprazole